Targeting Bcl-2 in CLL: cui bono?

Antagonizing function of Bcl-2 is an attractive goal in chronic lymphocytic leukemia (CLL) and other lymphoid malignancies. In this issue of Blood , Al-harbi et al describe a way to combine mRNA expression data from several Bcl-2 family members into a tool that predicts in vitro sensitivity of CLL

[1]  J. Maciejewski,et al.  An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. , 2011, Blood.

[2]  J. Waxman,et al.  CD3 limits the efficacy of TCR gene therapy in vivo. , 2011, Blood.

[3]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[5]  S. Rosenberg.  Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  M. Brenner.  T cell receptors and cancer: gain gives pain , 2010, Nature Medicine.

[7]  T. Schumacher,et al.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy , 2010, Nature Medicine.

[8]  H. Heslop,et al.  Adoptive T cell therapy of cancer. , 2010, Current opinion in immunology.

[9]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[10]  A. Letai,et al.  Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.

[11]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[12]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[13]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[14]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[15]  M. Merino,et al.  T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  John Calvin Reed,et al.  bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. , 1993, Blood.